Abstract: Fully dissolved, aqueous solutions of polycationic macromolecules and polyanionic macromolecules with a cell suspension are mixed to form a three dimensional hydrogel, useful for clinical, diagnostic, and therapeutic applications.

Abstract: Disclosed herein are dry blends of polyanionic and polycationic macromolecules, solvating fluids serving as cell suspension fluids, hybrid gel compositions, and methods for treatment of patients with endocrine disorders by transplantation with such compositions. Hybrid gel compositions that promote a microenvironment suitable for cell viability and growth while maintaining a sufficient structural integrity for three-dimensional cell culture are also disclosed.

Abstract: Disclosed herein are dry blends of polyanionic and polycationic macromolecules, solvating fluids serving as cell suspension fluids, hybrid gel compositions, and methods for treatment of patients with endocrine disorders by transplantation with such compositions. Hybrid gel compositions that promote a microenvironment suitable for cell viability and growth while maintaining a sufficient structural integrity for three-dimensional cell culture are also disclosed.

Abstract: Disclosed herein are dry blends of polyanionic and polycationic macromolecules, solvating fluids serving as cell suspension fluids, hybrid gel compositions, and methods for treatment of patients with endocrine disorders by transplantation with such compositions. Hybrid gel compositions that promote a microenvironment suitable for cell viability and growth while maintaining a sufficient structural integrity for three-dimensional cell culture are also disclosed.

Abstract: Disclosed herein are dry blends of polyanionic and polycationic macromolecules, solvating fluids serving as cell suspension fluids, hybrid gel compositions, and methods for treatment of patients with endocrine disorders by transplantation with such compositions. Hybrid gel compositions that promote a microenvironment suitable for cell viability and growth while maintaining a sufficient structural integrity for three-dimensional cell culture are also disclosed.

Abstract: An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. In one embodiment, the device is arranged for the local delivery of therapeutic agent. A preferred embodiment is a porous resorbable implant, wherein the therapy delivery may be localized in nature, rather than systemic, such that higher doses at the target site may be allowed than would be tolerable by the body systemically.

Abstract: An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.

Abstract: An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

Abstract: The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell progeny. The tissue engineering device and method of forming the same comprising hyaluronic acid and chitosan and the use of said device with compositions of pluripotent cells and various formulations of cell culture media for repair of tissues is disclosed.

Abstract: An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

Abstract: An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.

Abstract: An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

Abstract: An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.

Abstract: An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.

Abstract: The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell progeny. The tissue engineering device and method of forming the same comprising hyaluronic acid and chitosan and the use of said device with compositions of pluripotent cells and various formulations of cell culture media for repair of tissues is disclosed.

Abstract: The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell progeny. The tissue engineering device and method of forming the same comprising hyaluronic acid and chitosan and the use of said device with compositions of pluripotent cells and various formulations of cell culture media for repair of tissues is disclosed.

Abstract: An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

Abstract: An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

Abstract: An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. A hydrophobic barrier exists between the regions, of this embodiment. In one embodiment, the polyelectrolytic complex transforms to hydrogel, following the implant procedure.

Abstract: An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.